Rhythm Pharmaceuticals Inc (NASDAQ:RYTM) insider Bros. Advisors Lp Baker bought 885,000 shares of Rhythm Pharmaceuticals stock in a transaction on Thursday, October 5th. The stock was acquired at an average cost of $17.00 per share, with a total value of $15,045,000.00. The purchase was disclosed in a legal filing with the SEC, which is available at this link.

Shares of Rhythm Pharmaceuticals Inc (NASDAQ RYTM) opened at 25.25 on Friday. Rhythm Pharmaceuticals Inc has a 12-month low of $23.82 and a 12-month high of $30.55.

TRADEMARK VIOLATION NOTICE: This story was originally reported by Watch List News and is the property of of Watch List News. If you are viewing this story on another website, it was illegally stolen and republished in violation of United States & international copyright law. The correct version of this story can be accessed at https://www.watchlistnews.com/bros-advisors-lp-baker-purchases-885000-shares-of-rhythm-pharmaceuticals-inc-rytm-stock/1616657.html.

About Rhythm Pharmaceuticals

Rhythm Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of peptide therapeutics for the treatment of rare genetic deficiencies that result in life-threatening metabolic disorders. The Company’s lead peptide product candidate is setmelanotide, a potent, first-in-class melanocortin-4 receptor, or MC4R, agonist for the treatment of rare genetic disorders of obesity.

Receive News & Ratings for Rhythm Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rhythm Pharmaceuticals Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.